ARDX is expected to report earnings to fall 76.87% to -3 cents per share on July 30
Q2'26
Est.
$-0.03
Q1'26
Missed
by $0.02
Q4'25
Missed
by $0.02
Q3'25
Beat
by $0.06
Q2'25
Beat
by $0.05
The last earnings report on April 30 showed earnings per share of -15 cents, missing the estimate of -12 cents. With 1.73M shares outstanding, the current market capitalization sits at 1.27B.
A.I. Advisor
published General Information
General Information
a developer of therapeutic drugs that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases
A.I.dvisor indicates that over the last year, ARDX has been loosely correlated with VCYT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ARDX jumps, then VCYT could also see price increases.
ARDX sees its Stochastic Oscillator ascends from oversold territory
On July 09, 2026, the Stochastic Oscillator for ARDX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 59 instances where the indicator left the oversold zone. In of the 59 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ARDX's RSI Indicator exited the oversold zone, of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARDX advanced for three days, in of 260 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARDX as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ARDX turned negative on June 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
ARDX moved below its 50-day moving average on June 25, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for ARDX moved below the 200-day moving average on June 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ARDX broke above its upper Bollinger Band on June 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ARDX entered a downward trend on June 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ARDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.554) is normal, around the industry mean (22.885). P/E Ratio (0.000) is within average values for comparable stocks, (37.796). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.508). ARDX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (2.921) is also within normal values, averaging (434.181).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
